Solasia Pharma KK represents values of innovation, commitment, and patient-centricity in their corporate philosophy. As a leading pharmaceutical company, Solasia Pharma KK strives to develop and offer high-quality healthcare solutions for patients. With a strong focus on research and development, Solasia Pharma KK aims to bring innovative therapies and treatments to improve the lives of patients and support their well-being. Additionally, Solasia Pharma KK is committed to collaborating with healthcare professionals, partners, and stakeholders to address unmet medical needs and provide comprehensive support for patients throughout their treatment journey.

Solasia Pharma KK is primarily present in Japan and other key Asian markets. Japan, being Solasia Pharma KK's home country, serves as its primary base of operations. With a strong focus on oncology, Solasia Pharma KK aims to develop and deliver innovative cancer therapies to patients in need. Alongside Japan, Solasia Pharma KK has expanded its presence in other Asian regions, including China, South Korea, and Taiwan. By actively engaging in partnerships and collaborations, Solasia Pharma KK strives to bring its promising pharmaceutical products to diverse markets, contributing to the advancement of cancer treatment options in the region.

Solasia Pharma KK has achieved several significant milestones. The company successfully completed a Phase III clinical trial for its lead product darinaparsin, demonstrating its effectiveness in treating peripheral T-cell lymphoma. Solasia Pharma KK also received marketing approval in Taiwan for darinaparsin, allowing patients in need to access this innovative therapy. Additionally, the company forged strategic partnerships and collaborations with leading global pharmaceutical companies, further enhancing its research and development capabilities. These achievements reflect Solasia Pharma KK's commitment to advancing cancer treatments and improving patient outcomes.

Solasia Pharma KK is a reputable pharmaceutical company with a rich history and significant background. Established in [insert year], Solasia Pharma KK has dedicated itself to enhancing and transforming the healthcare industry. With a strong focus on developing innovative and cutting-edge solutions, Solasia Pharma KK aims to improve the lives of patients worldwide. The company prides itself on its extensive research and development efforts, consistently striving to bring novel therapies to market. Solasia Pharma KK's commitment to excellence and patient-centric approach has solidified its position as a trusted and influential player in the pharmaceutical industry.

The main competitors of Solasia Pharma KK in the market include other pharmaceutical companies operating in the same therapeutic area. Some key competitors for Solasia Pharma KK may include larger pharmaceutical companies such as Pfizer, Novartis, and Roche. These companies, along with other smaller biotech firms, may offer similar products or drug candidates targeting similar diseases or medical conditions. It is important to note that the competitive landscape in the pharmaceutical industry is dynamic and subject to change based on factors like market trends, product pipelines, and industry collaborations.

Solasia Pharma KK is primarily active in the pharmaceutical industry.

The business model of Solasia Pharma KK revolves around the development and commercialization of innovative oncology therapies in the Asian market. Solasia Pharma KK focuses on identifying and acquiring promising drug candidates from global pharmaceutical companies and advancing them through clinical trials and regulatory processes. By collaborating with key partners, Solasia Pharma KK aims to establish a strong market presence for its products and improve patient outcomes in areas of unmet medical needs. With a dedicated focus on oncology, Solasia Pharma KK strives to bring impactful treatments to patients and enhance the overall quality of cancer care in Asia.

Solasia Pharma KK Коефіцієнт P/E становить -7,71.

Коефіцієнт виручки від продажу Solasia Pharma KK становить 5,18.

АлеАкції індекс якості для Solasia Pharma KK складає 3/10.

очікувана Solasia Pharma KK обсяг продажів становить 1,37 млрд. JPY.

очікувана Solasia Pharma KK прибуток становить -923,74 млн. JPY.

Solasia Pharma KK is a pharmaceutical company based in Tokyo, Japan. The company specializes in the development and commercialization of oncology therapeutics, with a focus on clinical phase III and the market entry process. Solasia Pharma KK's business model is based on providing innovative medications in Japan and other Asian markets, aiming to bridge the gap between the clinical development of therapeutic agents and their market launch. The company has a range of products in various stages of development, including individual agents and combination products. Solasia Pharma KK works closely with partners and customers to successfully bring its products to the market. The company also leverages the opportunities in the Japanese market to facilitate access for foreign pharmaceutical companies, promoting knowledge exchange and collaboration in the field of clinical development. Strategic alliances and license agreements are vital components of Solasia Pharma KK's business model, enabling access to new agents, technologies, and expanding its research and development pipelines. The company's four main areas are research and development, clinical trials, regulatory affairs, and sales. Each department works closely together to ensure that all products meet the highest standards of quality, safety, and efficacy. With significant growth in recent years, Solasia Pharma KK is on its way to establishing itself as a leading oncology company in Asia. Due to its innovative business model and commitment to quality, safety, and efficacy, Solasia Pharma KK not only achieves growth but also contributes to improving healthcare in Asia.

Solasia Pharma KK виплачує дивіденд у розмірі 0 JPY, розподілений на виплати протягом року.

Дивіденди для Solasia Pharma KK на даний момент не можуть бути розраховані, або компанія не виплачує дивіденди.

ISIN Solasia Pharma KK є JP3436500007.

WKN Solasia Pharma KK становить A2DN9S.

Тікер Solasia Pharma KK це 4597.T.

Протягом останніх 12 місяців компанія Solasia Pharma KK виплатила дивіденд у розмірі . Це відповідає приблизній дивідендній дохідності . Очікується, що протягом наступних 12 місяців Solasia Pharma KK виплатить дивіденд у розмірі 0 JPY.

Дивідендна дохідність Solasia Pharma KK наразі становить .

Solasia Pharma KK виплачує дивіденди щоквартально. Вони виплачуються у місяцях .

Solasia Pharma KK протягом останніх 0 років щороку виплачував дивіденди.

На наступні 12 місяців очікується дивіденди у розмірі 0 JPY. Це відповідає дивідендній дохідності 0 %.

Solasia Pharma KK призначається до сектора "Здоров'я".

Щоб отримати останній дивіденд від Solasia Pharma KK від 09.11.2024 у розмірі 0 JPY, тобі потрібно було мати акцію в портфелі до дня Ex-Tag 09.11.2024.

Останню дивіденду було виплачено 09.11.2024.

У 2023 році компанія Solasia Pharma KK виплатила 0 JPY у вигляді дивідендів.

Дивіденди Solasia Pharma KK виплачуються у JPY.